NASDAQ · PROK
ProKidney Corp.
U.S. listed stock · USD15-minute delay
Find an instrument
- AppleAAPL · NASDAQResearch →
- MicrosoftMSFT · NASDAQResearch →
- NvidiaNVDA · NASDAQResearch →
- AmazonAMZN · NASDAQResearch →
- AlphabetGOOGL · NASDAQResearch →
- Meta PlatformsMETA · NASDAQResearch →
- TeslaTSLA · NASDAQResearch →
- JPMorgan ChaseJPM · NYSEResearch →
- ExxonMobilXOM · NYSEResearch →
- WalmartWMT · NASDAQResearch →
- S&P 500 IndexSPX · S&PResearch →
- Nasdaq 100 IndexNDX · NASDAQResearch →
- Dow Jones Industrial AverageDJI · Dow JonesResearch →
- Cboe Volatility IndexVIX · CboeResearch →
- U.S. Dollar IndexDXY · ICEResearch →
- VIX futuresVX1! · Cboe Futures ExchangeResearch →
- DAX futuresFDAX1! · EurexResearch →
- Euro Stoxx 50 futuresFESX1! · EurexResearch →
- E-mini S&P 500 futuresES1! · CMEResearch →
- E-mini Nasdaq 100 futuresNQ1! · CMEResearch →
- E-mini Dow futuresYM1! · CBOTResearch →
- E-mini Russell 2000 futuresRTY1! · CMEResearch →
- WTI crude oil futuresCL1! · NYMEXResearch →
- Natural gas futuresNG1! · NYMEXResearch →
- Gold futuresGC1! · COMEXResearch →
- Silver futuresSI1! · COMEXResearch →
- Euro FX futures6E1! · CMEResearch →
- Japanese yen futures6J1! · CMEResearch →
- BitcoinBTCUSD · BitstampResearch →
- EtherETHUSD · BitstampResearch →
- Research Any U.S. stock or ETF tickerResearch →
No matching names. Type a U.S. stock ticker (for example MU) to research it.
Loading price chart…
15-minute delay. Chart times and available timeframes are controlled by the provider.
Earnings
Earnings calendarEarnings announcement for PROK: Nov 9, 2026
ProKidney Corp. Class A Ordinary Shares is estimated to report earnings on 11/09/2026. The upcoming earnings date is derived from an algorithm based on a company's historical reporting dates. Our vendor, Zacks Investment Research, might revise this date in the future, once the company announces the actual earnings date. According to Zacks Investment Research, based on 2 analysts' forecasts, the consensus EPS forecast for the quarter is $-0.13. The reported EPS for the same quarter last year was $-0.12.
| Fiscal quarter end | Consensus EPS forecast | High | Low | Estimates |
|---|---|---|---|---|
| Sep 2026 | $-0.13 | $-0.12 | $-0.13 | 2 |
| Dec 2026 | $-0.11 | $-0.11 | $-0.11 | 2 |
| Mar 2027 | $-0.10 | $-0.10 | $-0.10 | 1 |
| Jun 2027 | $-0.10 | $-0.10 | $-0.10 | 1 |
Source: Nasdaq, based on Zacks Investment Research consensus estimates. Dates marked as expected may change.
News
MarketBeat · Fintel · Zacks · RTTNews- MarketBeat · Oct 28, 6:03 AM EDTProKidney Targets Q2 2027 Phase III Readout as Rilparencel Enrollment Surpasses 500ProKidney (NASDAQ:PROK) said it remains on track to report top-line results from the interim analysis of its Phase III PROACT 1 study in the second quarter of 2027, following stronger-than-expected patient recruitment for its investigational autologous cell therapy, rilparencel.
- Fintel · Oct 23, 4:20 PM EDTProKidney Consensus Price Target Raised by 10.40% to $7.04The average one-year price target for ProKidney (NASDAQCM:PROK) (BMV:PROK) has been revised to $7.04 / share. This is an increase of 10.40% from the prior estimate of $6.38 dated September 29, 2026. These figures represent aggregate analyst targets compiled by Fintel and do not c
- Zacks · Aug 10, 5:55 PM EDTProKidney Corp. (PROK) Reports Q2 Loss, Misses Revenue EstimatesPROKIDNEY CP (PROK) delivered earnings and revenue surprises of -15.39% and -31.82%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?
- Zacks · May 15, 12:55 PM EDTProKidney Corp. (PROK) Reports Q1 Loss, Tops Revenue EstimatesPROKIDNEY CP (PROK) delivered earnings and revenue surprises of -7.69% and +222.86%, respectively, for the quarter ended March 2026. Do the numbers hold clues to what lies ahead for the stock?
- Zacks · May 15, 7:10 AM EDTARS Pharmaceuticals, Inc. (SPRY) Reports Q1 Loss, Beats Revenue EstimatesARS Pharmaceuticals, Inc. (SPRY) delivered earnings and revenue surprises of -15.09% and +2.01%, respectively, for the quarter ended March 2026. Do the numbers hold clues to what lies ahead for the stock?
- Zacks · May 14, 8:45 AM EDTKaryopharm Therapeutics (KPTI) Reports Q1 Loss, Beats Revenue EstimatesKaryopharm Therapeutics (KPTI) delivered earnings and revenue surprises of +14.48% and +3.34%, respectively, for the quarter ended March 2026. Do the numbers hold clues to what lies ahead for the stock?
- RTTNews · Mar 19, 1:52 AM EDTProKidney Expects Phase 3 PROACT 1 Pivotal Trial Results For Rilparencel In Q2 2027(RTTNews) – ProKidney Corp. (PROK), a clinical-stage cell therapy company focused on chronic kidney disease or CKD, reported financial results for the full year 2025 and provided business highlights about its lead investigational candidate, Rilparencel or REACT.
- Zacks · Mar 12, 7:20 PM EDTKorro Bio, Inc. (KRRO) Reports Q4 Loss, Lags Revenue EstimatesKorro Bio, Inc. (KRRO) delivered earnings and revenue surprises of -175.08% and -13.87%, respectively, for the quarter ended December 2025. Do the numbers hold clues to what lies ahead for the stock?
- Zacks · Mar 4, 5:15 PM ESTAquestive Therapeutics (AQST) Reports Q4 Loss, Misses Revenue EstimatesAquestive Therapeutics (AQST) delivered earnings and revenue surprises of -100.00% and -2.64%, respectively, for the quarter ended December 2025. Do the numbers hold clues to what lies ahead for the stock?
- Fintel · Dec 21, 5:46 PM ESTProKidney (PROK) Price Target Increased by 15.10% to 6.85The average one-year price target for ProKidney (NasdaqCM:PROK) has been revised to $6.85 / share. This is an increase of 15.10% from the prior estimate of $5.95 dated December 3, 2025. The price target is an average of many targets provided by analysts. The l
- Fintel · Dec 16, 2:51 PM ESTHC Wainwright & Co. Initiates Coverage of ProKidney (PROK) with Buy RecommendationFintel reports that on December 16, 2025, HC Wainwright & Co. initiated coverage of ProKidney (NasdaqCM:PROK) with a Buy recommendation. Analyst Price Forecast Suggests 186.06% Upside
- RTTNews · Nov 10, 10:09 PM ESTPROKIDNEY CORP. Q3 Loss Decreases, Beats Estimates(RTTNews) – PROKIDNEY CORP. (PROK) reported Loss for third quarter that decreased from the same period last year and beat the Street estimates.
Stories from Nasdaq.com, including Zacks, The Motley Fool and Barchart. They open on the publisher’s site; AiFs Market does not edit or endorse them.
Company profile
Loading company profile…
Financials
Loading fundamental data…
More headlines
More stories for ProKidney Corp. from TradingView. Coverage varies.
Loading related news…
Quotes, charts, company information and headlines are supplied by TradingView. Data may be delayed or unavailable. This page is for market research and does not provide investment advice.